The stock price of X4 Pharmaceuticals Inc (NASDAQ: XFOR) has jumped by 7.94 compared to previous close of 1.26. Despite this, the company has seen a gain of 8.80% in its stock price over the last five trading days. GlobeNewsWire reported 2024-04-01 that BOSTON, April 01, 2024 (GLOBE NEWSWIRE) — X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in the upcoming Needham 23rd Annual Healthcare Conference being held virtually from April 8-11, 2024, and the Piper Sandler Spring Biopharma Symposium being held in Boston from April 16-17, 2024.
Is It Worth Investing in X4 Pharmaceuticals Inc (NASDAQ: XFOR) Right Now?
Moreover, the 36-month beta value for XFOR is 0.48. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for XFOR is 122.08M and currently, short sellers hold a 10.10% of that float. On April 23, 2024, XFOR’s average trading volume was 2.35M shares.
XFOR’s Market Performance
The stock of X4 Pharmaceuticals Inc (XFOR) has seen a 8.80% increase in the past week, with a 3.82% rise in the past month, and a 76.03% gain in the past quarter. The volatility ratio for the week is 10.07%, and the volatility levels for the past 30 days are at 11.26% for XFOR. The simple moving average for the past 20 days is 1.30% for XFOR’s stock, with a 26.45% simple moving average for the past 200 days.
Analysts’ Opinion of XFOR
Many brokerage firms have already submitted their reports for XFOR stocks, with B. Riley Securities repeating the rating for XFOR by listing it as a “Neutral.” The predicted price for XFOR in the upcoming period, according to B. Riley Securities is $1 based on the research report published on December 12, 2023 of the previous year 2023.
B. Riley Securities, on the other hand, stated in their research note that they expect to see XFOR reach a price target of $3. The rating they have provided for XFOR stocks is “Buy” according to the report published on August 30th, 2023.
Cantor Fitzgerald gave a rating of “Overweight” to XFOR, setting the target price at $3 in the report published on December 22nd of the previous year.
XFOR Trading at 23.25% from the 50-Day Moving Average
After a stumble in the market that brought XFOR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.18% of loss for the given period.
Volatility was left at 11.26%, however, over the last 30 days, the volatility rate increased by 10.07%, as shares sank -6.85% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +57.35% upper at present.
During the last 5 trading sessions, XFOR rose by +8.80%, which changed the moving average for the period of 200-days by -26.49% in comparison to the 20-day moving average, which settled at $1.3375. In addition, X4 Pharmaceuticals Inc saw 62.19% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at XFOR starting from Mostafa Adam S., who sale 52,500 shares at the price of $0.88 back on Mar 11 ’24. After this action, Mostafa Adam S. now owns 0 shares of X4 Pharmaceuticals Inc, valued at $46,347 using the latest closing price.
Ragan Paula, the President and CEO of X4 Pharmaceuticals Inc, sale 49,678 shares at $0.88 during a trade that took place back on Mar 11 ’24, which means that Ragan Paula is holding 765,068 shares at $43,856 based on the most recent closing price.
Stock Fundamentals for XFOR
The total capital return value is set at -0.84. Equity return is now at value -161.67, with -66.81 for asset returns.
Based on X4 Pharmaceuticals Inc (XFOR), the company’s capital structure generated 0.52 points at debt to capital in total, while cash flow to debt ratio is standing at -1.64. The debt to equity ratio resting at 1.09. The interest coverage ratio of the stock is -17.89.
Currently, EBITDA for the company is -105.53 million with net debt to EBITDA at 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.34.
Conclusion
To wrap up, the performance of X4 Pharmaceuticals Inc (XFOR) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
